

SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

Signant SmartSignals® Solutions for Covid-19 Vaccine Research

EXPEDITE COVID-19 VACCINE STUDIES WITHOUT COMPROMISING DATA QUALITY

COVID-19 vaccine research requires condensed timelines, flexible modes of conduct to accomodate patients and the highest quality data possible. Signant Health is prepared to meet these challenges with the experience and resources necessary to support global vaccine trials.

FASTER TRIALS, UNCOMPROMISED DATA ACCURACY

Take advantage of our decades of experience implementing eCOA in vaccine studies, which includes Signant's standard reactogenicity diary. With support from our science, medicine, and global clinical trial operations expertise, accelerate your COVID-19 vaccine studies without compromising endpoint data quality.

MANAGE LARGE-SCALE STUDIES WITH EASE

COVID-19 vaccine studies require substantial participant populations and sites to support them. Our RTSM, eConsent, and eCOA solutions will help you efficiently enroll and randomize participants, manage study supplies, and collect accurate data for studies involving tens of thousands of participants.

ADAPTIVE TRIAL DATA MANAGEMENT

When you partner with Signant, we ensure accuracy and precision of endpoint data. Our team completes data cleaning activities in time for interim analyses and design adaptations, allowing your team to derive insights, make quick decisions, and move rapidly between phases.

CONDUCT TRIAL ACTIVITIES REMOTELY

With study participants distributed across geographies, leverage our technology solutions to reduce site visit requirements, ensure consistent remote ratings, enable home-based data collection, and deliver study medications directly to patients. All solutions are delivered with expert project teams experienced in vaccine research.

SIMPLIFIED PHASE IV SAFETY AND EFFICACY DATA COLLECTION

Signant's eCOA, Telemedicine, and Patient Concierge solutions help researchers collect long term safety PRO data, minimize in-person site visit requirements, and improve participant retention in long-term COVID-19 vaccine follow up studies.

COMMON LIBRARY MEASURES USED IN CORONAVIRUS RESEARCH

- Signant's standard reactogenicity diary
- EQ-5D
- COVID-19 illness diary

ASK US FOR A COMPLETE LIST.

Signant supported a complex, 45,000-patient phase II/III COVID-19 vaccine study on an accelerated timeline, leading to the first fully approved COVID-19 vaccine in record time.

SIGNANT'S COVID-19 **EXPERIENCE BY THE NUMBERS**

I - III	24	1.1k	302k	15
PHASES	TRIALS	SITES	PATIENTS	COUNTRIES

DRIVE BETTER RESEARCH OUTCOMES WITH **SIGNANT SMARTSIGNALS SOLUTIONS**

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

LEARN MORE →

eCONSENT

LEARN MORE →

RTSM

LEARN MORE →

RATER TRAINING & QUALIFICATION

LEARN MORE →

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS →